Tous Actualités
Suivre
Abonner Bristol-Myers Squibb GmbH & Co. KGaA

Bristol-Myers Squibb GmbH & Co. KGaA

New Data on Four Bristol-Myers Squibb Compounds to be Presented at AASLD 2009

Princeton, New Jersey (ots/PRNewswire)

New data on four Bristol-Myers Squibb Company (NYSE: BMY)
compounds will be presented at the 60th annual meeting of the
American Association for the Study of Liver Diseases (AASLD) in
Boston from October 30 to November 3.
Data will be presented on BARACLUDE(R) (entecavir) in patients
with chronic hepatitis B, and on two compounds in early clinical
development for the treatment of hepatitis C -- BMS-650032, an NS3
inhibitor, and PEG-Interferon lambda, a novel type 3 interferon. The
presentation of data on BMS-650032 will mark the first public
disclosure of information about this investigational compound. Data
will also be presented on the investigational compound brivanib, the
first selective dual inhibitor of fibroblast growth factor (FGF) and
vascular endothelial growth factor (VEGF) signaling, which is in
Phase 3 development for the treatment of hepatocellular carcinoma.
"The data on Bristol-Myers Squibb compounds that will be
presented at AASLD demonstrate the breadth of our research and
development portfolio and support the company's goal of developing
innovative medicines for patients with various diseases of the
liver," said Elliott Sigal, M.D., Ph.D., executive vice president,
chief scientific officer and president, Research and Development,
Bristol-Myers Squibb. "Our established expertise in viral hepatitis
and oncology uniquely position Bristol-Myers Squibb to be at the
forefront of delivering innovation in the treatment of multiple types
and stages of liver disease. We are proud to be releasing new data on
our significant portfolio of assets."
BARACLUDE, BMS-650032 and brivanib were discovered by
Bristol-Myers Squibb Research and Development. BMS-650032 is
Bristol-Myers Squibb's second small molecule under development for
the treatment of hepatitis C, joining BMS-790052, a first-in-class
investigational NS5A inhibitor of the hepatitis C virus.
PEG-Interferon lambda was discovered by ZymoGenetics, Inc.
Bristol-Myers Squibb and ZymoGenetics announced a global
collaboration for PEG-Interferon lambda and its related development
program earlier this year.
The times, titles and lead authors of the data presentations are
as follows:
Date/Time       Presentation Title        Lead Author
    ---------       ------------------        -----------
    Hepatitis B
    October 31,     Efficacy and Safety of    Y. Liaw
    2:00 - 8:00     Entecavir versus          Chang Gung
    p.m. EDT        Adefovir in Chronic       Memorial Hospital,
                    Hepatitis B Patients      Chang Gung
                    with Evidence of          University
                    Hepatic                   College of Medicine
                    Decompensation            Taipei, Taiwan
                    (Abstract #422)
    Hepatitis C
    November 3,     Safety, Tolerability,     C. Pasquinelli
    12:00 - 12:15   Pharmacokinetics and      Bristol-Myers Squibb
    p.m. EST        Antiviral Activity
                    following Single- and
                    Multiple-Dose
                    Administration of
                    BMS-650032, a Novel
                    HCV NS3 Inhibitor, in
                    Subjects with Chronic
                    Genotype 1 HCV
                    Infection (Abstract
                    #225)
    November  3,    Genotypic and             F. McPhee
    8:00 a.m. -     Phenotypic Analysis       Bristol-Myers Squibb
    1:00 p.m. EST   of Samples from
                    HCV-Infected Subjects
                    Treated with
                    BMS-650032 in a
                    Single Ascending Dose
                    Study (Abstract #1607)
    November 3,     A Phase 1b                A.J. Muir
    8:00 a.m. -     Dose-Ranging Study of     Duke University
    1:00 p.m. EST   4 Weeks of                School of Medicine
                    PEG-Interferon (IFN)      Durham, North Carolina
                    Lambda (PEG-rIL-29)
                    in Combination with
                    Ribavirin (RBV) in
                    Patients with Chronic
                    Genotype 1 Hepatitis
                    C Virus (HCV)
                    Infection (Abstract
                    #1591)
    Hepatocellular Carcinoma
    November 3,     Time-to-Progression       R. Finn
    8:00 a.m. -     Analysis of               UCLA Los Angeles, CA
    1:00 p.m. EST   Second-line Treatment
                    with Brivanib in
                    Patients with
                    Unresectable, Locally
                    Advanced, or
                    Metastatic
                    Hepatocellular
                    Carcinoma (Abstract
                    #1683)
    November 3,     Cell-dependent            J. Park
    8:00 a.m. -     Response of               National Cancer Center
    1:00 p.m. EST   BMS-582664 (Brivanib)     Goyang, South Korea
                    in Hepatocellular
                    Carcinoma Cells: Gene
                    Expression Profiling
                    Study (Abstract #1668)
About BARACLUDE(R)
Discovered at Bristol-Myers Squibb, BARACLUDE(R) is a nucleoside
analogue indicated for use in adults with chronic hepatitis B
infection with compensated liver disease, evidence of active viral
replication, and either evidence of persistent elevations of the
blood levels of aminotransferases - a marker for liver disease - or
active liver disease as determined by biopsy. BARACLUDE (entecavir)
has been approved in more than 86 countries and regions around the
world.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company
committed to discovering, developing and delivering innovative
medicines that help patients prevail over serious diseases. For more
information, please visit www.bms.com.
BARACLUDE(R) (entecavir) is a registered trademark of
Bristol-Myers Squibb Company.

Contact:

Media, Annie Simond, office: +33-1-58-83-65-66, annie.simond@bms.com,
or Investors, John Elicker, +1-609-252-4611, john.elicker@bms.com

Plus de actualités: Bristol-Myers Squibb GmbH & Co. KGaA
Plus de actualités: Bristol-Myers Squibb GmbH & Co. KGaA
  • 31.03.2009 – 09:09

    Leading HIV Experts Convene to Tackle the Challenge of Late Presentation in Europe

    London (ots/PRNewswire) - - Between 15 to 38 percent of HIV-infected persons in Europe do not present for screening and treatment until late in infection.(1) Late presentation has been show to result in increased morbidity(1) and decreasing quality of life.(2,3) Almost three decades after the discovery of HIV/AIDS, and despite big medical advances, there ...